PR Newswire Clinical TrialsOriginal article
Spadek masy ciała o 19,3% po 48 tygodniach: na EASD zaprezentowano dane III fazy dotyczące olatorepatydu - agonisty receptorów GLP-1/GIP firmy Hansoh o ukierunkowanej sygnalizacji w obu receptorach
Phase 3positiveolatorepatidePositive
AI Analysis
Summary
Hansoh Pharma presented Phase 3 data for olatorepatide, a GLP-1/GIP receptor agonist, showing 19.3% body weight reduction after 48 weeks at the EASD annual meeting in Milan.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
19.3% body weight reduction after 48 weeks
Importance:7/10
Sentiment:
0.80
Phase 3 dataGLP-1/GIP agonistobesityweight lossEASD conferencedual receptor agonist
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 2, 2026 11:27 AM